Globus Medical, Inc. (NYSE:GMED) Stock Has Average Target Price of $101.77 According to Analysts

Posted by Brenda Bartman on Oct 2nd, 2026

Globus Medical, Inc. (NYSE:GMED – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seventeen brokerages that are presently covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating, nine have given a buy rating and three have assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $99.46.

Several equities analysts have recently weighed in on GMED shares. Royal Bank Of Canada decreased their price target on shares of Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a research note on Thursday. Wells Fargo & Company cut their price objective on shares of Globus Medical from $103.00 to $99.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Zacks Research upgraded shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, August 10th. Stifel Nicolaus decreased their target price on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating for the company in a research report on Wednesday, July 8th. Finally, UBS Group started coverage on shares of Globus Medical in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 price target on the stock.

Check Out Our Latest Analysis on GMED

Insider Buying and Selling

In other news, Director James Tobin sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the sale, the director owned 15,000 shares in the company, valued at $1,118,700. This represents a 66.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Stephen T. Zarrilli sold 25,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total value of $2,176,000.00. Following the completion of the sale, the director directly owned 25,000 shares of the company’s stock, valued at approximately $2,176,000. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. 18.38% of the stock is owned by company insiders.

Institutional Trading of Globus Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in GMED. Janus Henderson Group PLC grew its holdings in Globus Medical by 4.5% during the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock worth $656,831,000 after purchasing an additional 328,217 shares during the period. Sculptor Capital LP lifted its holdings in Globus Medical by 1.9% during the 1st quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock worth $263,477,000 after purchasing an additional 58,000 shares during the last quarter. Madison Avenue Partners LP boosted its stake in Globus Medical by 3.0% in the 4th quarter. Madison Avenue Partners LP now owns 2,624,751 shares of the medical device company’s stock valued at $229,167,000 after purchasing an additional 76,588 shares during the period. Dimensional Fund Advisors LP grew its holdings in Globus Medical by 2.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock valued at $152,474,000 after buying an additional 33,976 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in Globus Medical by 2.8% during the 1st quarter. The Manufacturers Life Insurance Company now owns 1,132,278 shares of the medical device company’s stock worth $97,557,000 after buying an additional 30,412 shares during the period. 95.16% of the stock is owned by institutional investors.

Globus Medical Price Performance

GMED opened at $74.44 on Tuesday. The business’s 50-day moving average price is $79.63 and its two-hundred day moving average price is $82.22. Globus Medical has a 1 year low of $56.50 and a 1 year high of $101.40. The company has a market capitalization of $9.99 billion, a price-to-earnings ratio of 19.04, a P/E/G ratio of 1.21 and a beta of 0.96.

Globus Medical (NYSE:GMED – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical device company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.24. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%.The company had revenue of $789.61 million for the quarter, compared to analyst estimates of $782.88 million. During the same period in the previous year, the company posted $0.86 earnings per share. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Sell-side analysts anticipate that Globus Medical will post 4.99 earnings per share for the current fiscal year.

About Globus Medical

(Get Free Report)

Globus Medical, Inc is a medical device company that develops musculoskeletal solutions for surgeons, hospitals and ambulatory surgery centers. Its primary focus is the design, development and commercialization of products used in spinal surgery, including implants, instruments, navigation systems and robotic-assisted technologies.

The company’s portfolio includes the ExcelsiusGPS robotic navigation platform, Excelsius3D imaging technology, spinal implants and systems for procedures such as deformity correction, degenerative spine treatment and minimally invasive surgery.